Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial
Resource Type
Article
Authors
Aurora, Paul ; Verhulst, Stijn ; Watson, Danie ; Lorenz, Michael ; Roehmel, Jobst ; Gleiber, Wolfgang ; Naehrig, Susanne ; Stehling, Florian ; Sutharsan, Sivagurunathan ; van Koningsbruggen-Rietschel, Silke ; Fischer, Rainald ; Downey, Damian ; Haworth, Charles ; Duckers, Jamie ; Legg, Julian ; Barry, Peter ; Thursfield, Rebecca ; Doe, Simon James ; Hilliard, Tom ; MacGregor, Gordon ; Nash, Edward F ; Withers, Nicholas John ; Peckham, Daniel ; Barr, Helen Louise ; Lee, Timothy ; Gray, Robert ; Vermeulen, Francois ; Van Braeckel, Eva ; Vanderhelst, Eef ; Robinson, Philip J ; Wainwright, Claire E ; Smith, Daniel J ; Mulrennan, Siobhain A ; Clements, Barry S ; Wark, Peter ; McKone, Edward F ; Downey, Damian G ; Tullis, Elizabeth ; Ahluwalia, Neil ; Bruinsma, Bote G ; Harris, Christopher ; Lam, Anna P ; Lou, Yiyue ; Moskowitz, Samuel M ; Tian, Simon ; Yuan, Jason ; Waltz, David ; Mall, Marcus A
Source
In The Lancet Respiratory Medicine March 2022 10(3):267-277
Subject
Primary Research Articles
Language
ISSN
2213-2600